Cytovance Biologics, Inc. has expanded its Keystone Expression System to address obstacles for researchers using the Gram-negative bacterium, E. coli, related to cost of goods, scale-up challenges, or in-process control. Cytovance Biologics has developed an E. coli expression platform using a toolbox approach to gene design, host construction, and screening evaluation. According to the company, partnering of DNA2.0’s GeneGPS Codon Optimization with its Keystone Expression System create...